CYP2C19基因多态性对基于雷贝拉唑的根除幽门螺杆菌联合疗法没有影响。
CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for eradication.
作者信息
Lin Tsung-Jung, Lee Hsi-Chang, Lin Chih-Lin, Wang Chung-Kwe, Chen Kuan-Yang, Wu Deng-Chyang
机构信息
Department of Health care and Social Work, Taipei University of Marine Technology, New Taipei 25172, Taiwan.
Department of Gastroenterology, Taipei City Hospital, Taipei 10629, Taiwan.
出版信息
World J Clin Cases. 2018 Oct 26;6(12):514-520. doi: 10.12998/wjcc.v6.i12.514.
AIM
To evaluate the impact of cytochrome P450 2C19 (CYP2C19) and interleukin-1β (IL-1β) polymorphisms on the efficacy of () eradication by using rabeprazole-based hybrid therapy.
METHODS
A total of 88 -infected patients were recruited to receive 14-d of hybrid therapy from March 2013 to May 2014. Three patients were excluded from analysis because of incomplete compliance. Either a follow-up endoscopy or C-urea test was performed to determine the results of eradication therapy. The genotypes of CYP2C19 and IL-1β were analyzed to investigate the impact on treatment effect.
RESULTS
The total eradication rate of was 92.94% (79/85). According to the CYP2C19 genotypes, the rates of eradication were 89.19% in extensive metabolizers (EM) and 95.83% in non-EM. The eradication rates regarding the IL-1β genotypes were 92.59% in the normal acid secretion group and 93.10% in the low acid secretion group. After multivariable logistic regression analysis, both the genotypes of CYP2C19 and IL-1β had no significant influences on the eradication rates of .
CONCLUSION
The CYP2C19 and IL-1β polymorphisms are not significantly independent factors of eradication using rabeprazole-based hybrid therapy.
目的
评估细胞色素P450 2C19（CYP2C19）和白细胞介素-1β（IL-1β）基因多态性对基于雷贝拉唑的联合疗法根除（）疗效的影响。
方法
2013年3月至2014年5月，共招募了88例（）感染患者接受为期14天的联合疗法。3例患者因依从性不完全而被排除在分析之外。通过后续内镜检查或C-尿素呼气试验来确定根除治疗的结果。分析CYP2C19和IL-1β的基因型，以研究其对治疗效果的影响。
结果
（）的总根除率为92.94%（79/85）。根据CYP2C19基因型，广泛代谢者（EM）的（）根除率为89.19%，非广泛代谢者为95.83%。关于IL-1β基因型，正常胃酸分泌组的（）根除率为92.59%，低胃酸分泌组为93.10%。多变量逻辑回归分析后，CYP2C19和IL-1β的基因型对（）根除率均无显著影响。
结论
CYP2C19和IL-1β基因多态性不是基于雷贝拉唑的联合疗法根除（）的显著独立因素。
Zotero 插件